|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
alborixin results in increased expression of BAX protein |
CTD |
PMID:27378626 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
alborixin results in decreased expression of BCL2 protein |
CTD |
PMID:27378626 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
increases cleavage |
ISO |
alborixin results in increased cleavage of CASP3 protein |
CTD |
PMID:27378626 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
alborixin results in increased activity of CASP8 protein |
CTD |
PMID:27378626 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
alborixin results in increased activity of CASP9 protein |
CTD |
PMID:27378626 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
alborixin results in increased cleavage of PARP1 protein |
CTD |
PMID:27378626 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
decreases expression multiple interactions |
ISO |
azadirachtin results in decreased expression of ACP5 mRNA azadirachtin inhibits the reaction [Estrogens deficiency results in increased expression of ACP5 mRNA] |
CTD |
PMID:31225646 |
|
NCBI chr 8:28,939,984...28,946,639
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression |
ISO |
azadirachtin results in increased expression of APAF1 protein |
CTD |
PMID:20429769 |
|
NCBI chr 7:27,381,392...27,466,772
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression |
ISO |
azadirachtin results in increased expression of BAD mRNA |
CTD |
PMID:20429769 |
|
NCBI chr 1:213,562,719...213,572,034
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
azadirachtin results in increased expression of BAX mRNA |
CTD |
PMID:20429769 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
azadirachtin results in decreased expression of BCL2 mRNA; azadirachtin results in decreased expression of BCL2 protein |
CTD |
PMID:20429769 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
azadirachtin results in decreased expression of BCL2L1 mRNA |
CTD |
PMID:20429769 |
|
NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
azadirachtin inhibits the reaction [Estrogens deficiency results in increased expression of BGLAP protein] |
CTD |
PMID:31225646 |
|
NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases expression |
ISO |
azadirachtin results in increased expression of BID mRNA |
CTD |
PMID:20429769 |
|
NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
azadirachtin results in decreased expression of BIRC5 protein |
CTD |
PMID:20429769 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
increases expression |
ISO |
azadirachtin results in increased expression of BMP2 mRNA; azadirachtin results in increased expression of BMP2 protein |
CTD |
PMID:31225646 |
|
NCBI chr 3:141,264,648...141,275,416
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Casp3 |
caspase 3 |
increases expression |
ISO |
azadirachtin results in increased expression of CASP3 mRNA; azadirachtin results in increased expression of CASP3 protein |
CTD |
PMID:20429769 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp6 |
caspase 6 |
increases expression |
ISO |
azadirachtin results in increased expression of CASP6 protein |
CTD |
PMID:20429769 |
|
NCBI chr 2:221,140,287...221,152,727
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp8 |
caspase 8 |
increases expression |
ISO |
azadirachtin results in increased expression of CASP8 protein |
CTD |
PMID:20429769 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
azadirachtin results in increased expression of CASP9 mRNA; azadirachtin results in increased expression of CASP9 protein |
CTD |
PMID:20429769 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
azadirachtin results in decreased expression of CCND1 mRNA |
CTD |
PMID:20429769 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
azadirachtin results in increased expression of CDKN1A mRNA; azadirachtin results in increased expression of CDKN1A protein |
CTD |
PMID:20429769 |
|
NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cycs |
cytochrome c, somatic |
increases expression affects localization |
ISO |
azadirachtin results in increased expression of CYCS mRNA azadirachtin affects the localization of CYCS protein |
CTD |
PMID:20429769 |
|
NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression multiple interactions affects binding |
ISO |
azadirachtin results in increased expression of ESR1 mRNA; azadirachtin results in increased expression of ESR1 protein 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [azadirachtin results in increased expression of ESR1 mRNA]; 1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [azadirachtin results in increased expression of ESR1 protein]; azadirachtin inhibits the reaction [Estrogens deficiency results in decreased expression of ESR1 mRNA]; ESR1 protein promotes the reaction [azadirachtin results in increased expression of RUNX2 mRNA]; ESR1 protein promotes the reaction [azadirachtin results in increased expression of RUNX2 protein] azadirachtin binds to ESR1 protein |
CTD |
PMID:31225646 |
|
NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions affects binding increases expression |
ISO |
azadirachtin inhibits the reaction [Estrogens deficiency results in decreased expression of ESR2 mRNA] azadirachtin binds to ESR2 protein azadirachtin results in increased expression of ESR2 mRNA; azadirachtin results in increased expression of ESR2 protein |
CTD |
PMID:31225646 |
|
NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
decreases expression |
ISO |
azadirachtin results in decreased expression of IKBKB protein |
CTD |
PMID:20429769 |
|
NCBI chr16:76,021,968...76,075,717
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
azadirachtin results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:31225646 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
azadirachtin results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:31225646 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
decreases expression |
ISO |
azadirachtin results in decreased expression of NFKB1 protein |
CTD |
PMID:20429769 |
|
NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases expression |
ISO |
azadirachtin results in decreased expression of NFKBIA protein modified form |
CTD |
PMID:20429769 |
|
NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression |
ISO |
azadirachtin results in decreased expression of PCNA mRNA; azadirachtin results in decreased expression of PCNA protein |
CTD |
PMID:20429769 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases expression |
ISO |
azadirachtin results in decreased expression of RELA protein |
CTD |
PMID:20429769 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression multiple interactions |
ISO |
azadirachtin results in increased expression of RUNX2 mRNA; azadirachtin results in increased expression of RUNX2 protein ESR1 protein promotes the reaction [azadirachtin results in increased expression of RUNX2 mRNA]; ESR1 protein promotes the reaction [azadirachtin results in increased expression of RUNX2 protein] |
CTD |
PMID:31225646 |
|
NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Smad1 |
SMAD family member 1 |
increases expression |
ISO |
azadirachtin results in increased expression of SMAD1 protein modified form |
CTD |
PMID:31225646 |
|
NCBI chr19:45,417,430...45,477,962
Ensembl chr19:28,513,131...28,573,651
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression |
ISO |
azadirachtin results in decreased expression of TNF mRNA |
CTD |
PMID:31225646 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11a |
TNF receptor superfamily member 11A |
multiple interactions decreases expression |
ISO |
azadirachtin inhibits the reaction [Estrogens deficiency results in increased expression of TNFRSF11A mRNA] azadirachtin results in decreased expression of TNFRSF11A mRNA |
CTD |
PMID:31225646 |
|
NCBI chr13:22,442,930...22,501,257
Ensembl chr13:21,928,408...21,986,695
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
azadirachtin results in increased expression of TP53 mRNA; azadirachtin results in increased expression of TP53 protein |
CTD |
PMID:20429769 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [AGT protein affects the localization of Calcium] |
CTD |
PMID:21613610 |
|
NCBI chr19:69,426,540...69,447,017
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Aim2 |
absent in melanoma 2 |
multiple interactions |
ISO |
[bafilomycin A1 co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of AIM2 protein |
CTD |
PMID:32645460 |
|
NCBI chr13:88,397,516...88,439,325
Ensembl chr13:85,866,284...85,906,975
|
|
G |
Akt1s1 |
AKT1 substrate 1 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of AKT1S1 protein]; bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]] |
CTD |
PMID:22689575 PMID:37914286 |
|
NCBI chr 1:104,469,823...104,476,168
Ensembl chr 1:95,332,898...95,339,677
|
|
G |
Alb |
albumin |
decreases uptake |
ISO |
bafilomycin A1 results in decreased uptake of ALB protein |
CTD |
PMID:16313995 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression |
ISO |
bafilomycin A1 results in increased expression of APAF1 protein |
CTD |
PMID:28483490 |
|
NCBI chr 7:27,381,392...27,466,772
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Appl1 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 |
multiple interactions |
ISO |
bafilomycin A1 promotes the reaction [Lipopolysaccharides results in increased degradation of APPL1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased degradation of APPL1 protein] |
CTD |
PMID:25780039 |
|
NCBI chr16:2,125,234...2,173,457
Ensembl chr16:2,121,255...2,166,692
|
|
G |
Arf6 |
ARF GTPase 6 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [maduramicin results in decreased expression of ARF6 protein] |
CTD |
PMID:37394175 |
|
NCBI chr 6:93,589,777...93,590,925
Ensembl chr 6:87,840,142...87,874,114
|
|
G |
Asic1 |
acid sensing ion channel subunit 1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Freund's Adjuvant results in increased expression of ASIC1 mRNA] |
CTD |
PMID:16769263 |
|
NCBI chr 7:130,798,317...130,828,535
Ensembl chr 7:130,799,917...130,828,541
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
ISO |
ATG5 protein affects the reaction [bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]] [bafilomycin A1 co-treated with Swainsonine] results in increased expression of ATG5 mRNA; [bafilomycin A1 co-treated with Swainsonine] results in increased lipidation of ATG5 protein |
CTD |
PMID:29938581 PMID:36402259 |
|
NCBI chr20:49,380,835...49,471,826
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Hydroxychloroquine results in increased activity of BAX protein] |
CTD |
PMID:12813466 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
bafilomycin A1 results in decreased expression of BCL2 mRNA bafilomycin A1 promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein] |
CTD |
PMID:31310755 PMID:34374793 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Becn1 |
beclin 1 |
multiple interactions increases expression |
ISO EXP |
bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of BECN1 protein] [Swainsonine co-treated with bafilomycin A1] results in increased expression of BECN1 protein; bafilomycin A1 promotes the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of BECN1 protein] bafilomycin A1 results in increased expression of BECN1 protein |
CTD |
PMID:32645460 PMID:33186601 PMID:33242459 |
|
NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA] |
CTD |
PMID:23111315 |
|
NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions increases cleavage increases expression |
EXP ISO |
bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of BID protein modified form]; bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of BID protein] vistusertib affects the reaction [bafilomycin A1 results in increased cleavage of BID protein] bafilomycin A1 results in increased expression of BID protein modified form |
CTD |
PMID:26853465 PMID:28378122 |
|
NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression multiple interactions |
ISO |
bafilomycin A1 results in increased expression of BNIP3 mRNA; bafilomycin A1 results in increased expression of BNIP3 protein BNIP3 mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; capivasertib affects the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; Erlotinib Hydrochloride inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; Gefitinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; HIF1A mutant form inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; vistusertib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein] |
CTD |
PMID:25981168 PMID:26853465 |
|
NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Casp3 |
caspase 3 |
decreases activity increases cleavage multiple interactions increases activity |
ISO EXP |
bafilomycin A1 results in decreased activity of CASP3 protein bafilomycin A1 results in increased cleavage of CASP3 protein bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of CASP3 protein] bafilomycin A1 results in increased activity of CASP3 protein [Swainsonine co-treated with bafilomycin A1] results in increased cleavage of CASP3 protein; bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [Hydrogen Peroxide results in increased expression of CASP3 protein modified form]; bafilomycin A1 promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein] [bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein; [bafilomycin A1 co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein; [bafilomycin A1 co-treated with methanandamide] results in increased cleavage of CASP3 protein; [Cannabidiol co-treated with bafilomycin A1] results in increased cleavage of CASP3 protein; bafilomycin A1 inhibits the reaction [Soot analog results in increased expression of CASP3 protein]; bafilomycin A1 inhibits the reaction [tetrandrine results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [brazilin results in increased activity of CASP3 protein]; bafilomycin A1 promotes the reaction [fosbretabulin results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [[bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [[bafilomycin A1 co-treated with methanandamide] results in increased cleavage of CASP3 protein]; vistusertib affects the reaction [bafilomycin A1 results in increased cleavage of CASP3 protein] |
CTD |
PMID:20876807 PMID:23380477 PMID:24321340 PMID:24889822 PMID:25266202 PMID:25981168 PMID:26853465 PMID:28063998 PMID:28378122 PMID:29111403 PMID:30240709 PMID:32708634 PMID:33076330 PMID:33186601 PMID:34374793 More...
|
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
increases activity |
ISO |
bafilomycin A1 results in increased activity of CASP4 protein |
CTD |
PMID:20371669 |
|
NCBI chr 8:10,883,817...10,919,978
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp7 |
caspase 7 |
increases activity decreases activity |
ISO |
bafilomycin A1 results in increased activity of CASP7 protein bafilomycin A1 results in decreased activity of CASP7 protein |
CTD |
PMID:20371669 PMID:25981168 |
|
NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
EXP ISO |
bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP8 protein] bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of CASP8 protein] |
CTD |
PMID:28378122 PMID:29111403 |
|
NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP ISO |
bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP9 protein] bafilomycin A1 inhibits the reaction [Soot analog results in increased expression of CASP9 protein] |
CTD |
PMID:28378122 PMID:30240709 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Dexamethasone results in decreased expression of CCND1 protein] |
CTD |
PMID:33359579 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdc25c |
cell division cycle 25C |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [xanthatin results in decreased stability of CDC25C protein] |
CTD |
PMID:29074359 |
|
NCBI chr18:26,608,483...26,630,292
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Capsaicin results in increased expression of CDH1 protein] |
CTD |
PMID:36044967 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Capsaicin results in decreased expression of CDH2 protein] |
CTD |
PMID:36044967 |
|
NCBI chr18:8,051,097...8,265,288
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein]; bafilomycin A1 inhibits the reaction [Hydroxychloroquine affects the localization of CTSB protein] |
CTD |
PMID:12813466 PMID:23380477 |
|
NCBI chr15:41,565,607...41,586,479
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsd |
cathepsin D |
decreases cleavage |
ISO |
bafilomycin A1 results in decreased cleavage of CTSD protein |
CTD |
PMID:36070022 |
|
NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsl |
cathepsin L |
decreases cleavage |
ISO |
bafilomycin A1 results in decreased cleavage of CTSL protein |
CTD |
PMID:36070022 |
|
NCBI chr17:770,104...776,266
Ensembl chr17:764,309...770,548
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [CpG ODN 2216 results in increased expression of CXCL10 protein]; bafilomycin A1 inhibits the reaction [gardiquimod results in increased expression of CXCL10 protein]; bafilomycin A1 inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein] |
CTD |
PMID:26682054 |
|
NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression multiple interactions |
EXP |
bafilomycin A1 results in increased expression of DDIT4 protein [EGF protein co-treated with bafilomycin A1] results in increased expression of DDIT4 protein |
CTD |
PMID:22689575 |
|
NCBI chr20:28,434,938...28,437,037
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Deptor |
DEP domain containing MTOR-interacting protein |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]] |
CTD |
PMID:37914286 |
|
NCBI chr 7:88,404,745...88,574,065
Ensembl chr 7:86,514,988...86,667,773
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
EXP |
[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine; [bafilomycin A1 co-treated with EGF protein] results in increased abundance of Aspartic Acid; [bafilomycin A1 co-treated with EGF protein] results in increased abundance of Taurine; [EGF protein co-treated with bafilomycin A1] results in increased expression of DDIT4 protein; bafilomycin A1 inhibits the reaction [EGF protein results in increased activity of and results in increased phosphorylation of RPS6KB1 protein]; bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of AKT1S1 protein]; bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of EIF4EBP1 protein]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine] |
CTD |
PMID:22689575 |
|
NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Arsenic Trioxide results in decreased expression of EGFR protein] |
CTD |
PMID:30237564 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of EIF4EBP1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:22689575 |
|
NCBI chr16:71,495,457...71,508,845
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Epor |
erythropoietin receptor |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Aristolochic Acids results in increased degradation of and results in decreased expression of EPOR protein] |
CTD |
PMID:26136230 |
|
NCBI chr 8:28,765,738...28,770,371
Ensembl chr 8:20,489,678...20,494,257
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO EXP |
bafilomycin A1 inhibits the reaction [FASL protein affects the localization of Calcium] bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of FASLG protein] |
CTD |
PMID:20200208 PMID:28378122 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fmc1 |
formation of mitochondrial complex V assembly factor 1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of FMC1 protein] |
CTD |
PMID:29371327 |
|
NCBI chr 4:68,241,009...68,249,045
Ensembl chr 4:67,274,104...67,282,140
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [resveratrol inhibits the reaction [Hydrogen Peroxide results in increased acetylation of FOXO1 protein]] |
CTD |
PMID:24889822 |
|
NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions |
ISO |
bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTH1 protein] |
CTD |
PMID:37951334 |
|
NCBI chr 1:216,052,037...216,054,325
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Ftl1 |
ferritin light chain 1 |
multiple interactions |
ISO |
bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTL protein] |
CTD |
PMID:37951334 |
|
NCBI chr 1:105,072,858...105,074,705
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725 Ensembl chr 2:95,936,387...95,939,725
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression |
ISO |
bafilomycin A1 results in increased expression of GJA1 protein |
CTD |
PMID:35750204 |
|
NCBI chr20:36,302,490...36,315,010
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression multiple interactions |
ISO |
bafilomycin A1 results in increased expression of HIF1A protein HIF1A mutant form inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; HIF1A mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of HIF1A protein] |
CTD |
PMID:25981168 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression multiple interactions |
ISO |
bafilomycin A1 results in decreased expression of HMOX1 protein [bafilomycin A1 co-treated with methanandamide] results in increased expression of HMOX1 protein; [bafilomycin A1 co-treated with tin protoporphyrin IX] promotes the reaction [Cannabidiol results in increased expression of HMOX1 protein]; bafilomycin A1 inhibits the reaction [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole results in increased expression of HMOX1 protein] |
CTD |
PMID:29796178 PMID:33076330 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ifng |
interferon gamma |
decreases expression |
ISO |
bafilomycin A1 results in decreased expression of IFNG mRNA |
CTD |
PMID:16932910 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO |
bafilomycin A1 results in decreased expression of IL1B mRNA [bafilomycin A1 co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of IL1B protein; bafilomycin A1 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein] |
CTD |
PMID:16932910 PMID:24158569 PMID:32645460 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
bafilomycin A1 results in increased expression of IL6 mRNA |
CTD |
PMID:16932910 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
bafilomycin A1 promotes the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] |
CTD |
PMID:32283200 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of EIF4EBP1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:22689575 |
|
NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
bafilomycin A1 promotes the reaction [pachastrissamine analog promotes the reaction [KEAP1 protein binds to SQSTM1 protein]] |
CTD |
PMID:35123989 |
|
NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lamp1 |
lysosomal-associated membrane protein 1 |
multiple interactions increases expression |
ISO |
[bafilomycin A1 co-treated with Swainsonine] results in increased expression of LAMP1 mRNA; [bafilomycin A1 co-treated with Swainsonine] results in increased expression of LAMP1 protein bafilomycin A1 results in increased expression of LAMP1 protein |
CTD |
PMID:36402259 |
|
NCBI chr16:83,058,131...83,082,843
Ensembl chr16:76,355,984...76,381,883
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
multiple interactions |
EXP |
bafilomycin A1 promotes the reaction [C1QTNF9 protein results in increased expression of MAP1LC3B protein modified form] |
CTD |
PMID:32278738 |
|
NCBI chr19:50,744,598...50,748,064
Ensembl chr19:33,834,403...33,838,231
|
|
G |
Lrrk2 |
leucine-rich repeat kinase 2 |
increases response to substance |
ISO |
LRRK2 gene mutant form results in increased susceptibility to bafilomycin A1 |
CTD |
PMID:25017139 |
|
NCBI chr 7:124,706,246...124,867,234
Ensembl chr 7:122,826,696...122,987,703
|
|
G |
Man2a1 |
mannosidase, alpha, class 2A, member 1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Swainsonine results in decreased expression of MAN2A1 mRNA] |
CTD |
PMID:36402259 |
|
NCBI chr 9:111,698,913...111,855,257
Ensembl chr 9:104,252,001...104,408,349
|
|
G |
Man2b1 |
mannosidase, alpha, class 2B, member 1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Swainsonine results in decreased expression of MAN2B1 mRNA] |
CTD |
PMID:36402259 |
|
NCBI chr19:39,959,964...39,979,299
Ensembl chr19:23,055,097...23,074,389
|
|
G |
Map1lc3a |
microtubule-associated protein 1 light chain 3 alpha |
multiple interactions increases expression |
ISO EXP |
bafilomycin A1 promotes the reaction [Uranium results in increased expression of MAP1LC3A protein] bafilomycin A1 inhibits the reaction [Lidocaine results in increased expression of MAP1LC3A protein] bafilomycin A1 results in increased expression of MAP1LC3A protein modified form |
CTD |
PMID:30871063 PMID:31120128 PMID:37914286 |
|
NCBI chr 3:164,243,204...164,244,850
Ensembl chr 3:143,783,024...143,784,670
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases lipidation increases expression increases cleavage decreases degradation |
ISO EXP |
[bafilomycin A1 co-treated with Miconazole] results in increased expression of MAP1LC3B protein; [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone co-treated with bafilomycin A1] results in increased expression of MAP1LC3B mRNA; [TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form; Acetylcysteine inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone promotes the reaction [bafilomycin A1 results in increased expression of MAP1LC3B protein]]; ATG5 protein affects the reaction [bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]]; bafilomycin A1 affects the reaction [Ammonium Chloride results in increased metabolism of MAP1LC3B protein]; bafilomycin A1 affects the reaction [AZD4547 affects the expression of MAP1LC3B protein modified form]; bafilomycin A1 affects the reaction [AZD8186 affects the expression of MAP1LC3B protein modified form]; bafilomycin A1 inhibits the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [[alpha-Chlorohydrin co-treated with Diosgenin] results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [capivasertib results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [Curcumin results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [metarrestin results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [Miconazole results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [ovatodiolide results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [Particulate Matter results in increased expression of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [Resveratrol results in increased expression of MAP1LC3B protein alternative form]; bafilomycin A1 promotes the reaction [Sevoflurane results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [vistusertib results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 results in increased expression of and results in increased lipidation of MAP1LC3B protein; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone promotes the reaction [bafilomycin A1 results in increased expression of MAP1LC3B protein]; Resveratrol promotes the reaction [[TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form] bafilomycin A1 results in increased lipidation of MAP1LC3B protein [Doxorubicin co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein; [Glycyrrhizic Acid co-treated with bafilomycin A1] results in increased lipidation of MAP1LC3B protein; bafilomycin A1 inhibits the reaction [olaparib inhibits the reaction [Hydrogen Peroxide results in increased lipidation of MAP1LC3B protein]]; bafilomycin A1 promotes the reaction [C1QTNF9 protein results in increased expression of MAP1LC3B protein modified form] bafilomycin A1 results in increased expression of MAP1LC3B protein modified form [bafilomycin A1 co-treated with Swainsonine] results in increased expression of MAP1LC3B mRNA; [bafilomycin A1 co-treated with Swainsonine] results in increased lipidation of MAP1LC3B protein; bafilomycin A1 promotes the reaction [tricalcium phosphate results in increased expression of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [Triiodothyronine results in increased lipidation of MAP1LC3B protein]; Triiodothyronine promotes the reaction [bafilomycin A1 results in increased lipidation of MAP1LC3B protein] bafilomycin A1 results in increased cleavage of MAP1LC3B protein bafilomycin A1 results in decreased degradation of MAP1LC3B protein modified form bafilomycin A1 results in increased expression of MAP1LC3B protein; bafilomycin A1 results in increased expression of MAP1LC3B protein alternative form; bafilomycin A1 results in increased expression of MAP1LC3B protein modified form |
CTD |
PMID:23880069 PMID:24145604 PMID:25301941 PMID:26459185 PMID:26853465 PMID:27305347 PMID:29248574 PMID:29524503 PMID:29908302 PMID:29938581 PMID:30209975 PMID:31310755 PMID:32278738 PMID:32525084 PMID:32981224 PMID:33124469 PMID:34580807 PMID:34634291 PMID:35149085 PMID:35472370 PMID:35872226 PMID:36070022 PMID:36402259 PMID:36639873 PMID:37678662 PMID:38000454 More...
|
|
NCBI chr19:66,571,631...66,582,270
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases expression |
ISO |
bafilomycin A1 inhibits the reaction [Capsaicin results in increased activity of MAPK1 protein]; bafilomycin A1 inhibits the reaction [Iron Compounds results in increased expression of MAPK1 protein modified form]; bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK1 protein] bafilomycin A1 results in increased expression of MAPK1 protein modified form |
CTD |
PMID:20371669 PMID:28483490 PMID:32645460 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases expression |
ISO |
bafilomycin A1 inhibits the reaction [Capsaicin results in increased activity of MAPK3 protein]; bafilomycin A1 inhibits the reaction [Iron Compounds results in increased expression of MAPK3 protein modified form]; bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK3 protein] bafilomycin A1 results in increased expression of MAPK3 protein modified form |
CTD |
PMID:20371669 PMID:28483490 PMID:32645460 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation |
ISO |
bafilomycin A1 results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:31310755 |
|
NCBI chr16:8,645,171...8,728,225
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mlst8 |
MTOR associated protein, LST8 homolog |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]] |
CTD |
PMID:37914286 |
|
NCBI chr10:14,002,927...14,008,678
Ensembl chr10:13,498,388...13,504,128
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation multiple interactions |
ISO EXP |
bafilomycin A1 results in decreased phosphorylation of MTOR protein bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]] |
CTD |
PMID:31310755 PMID:37914286 |
|
NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression |
ISO |
bafilomycin A1 results in increased expression of MTTP protein |
CTD |
PMID:34516972 |
|
NCBI chr 2:229,286,501...229,327,650
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Ncoa4 |
nuclear receptor coactivator 4 |
multiple interactions |
ISO |
bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of NCOA4 protein] |
CTD |
PMID:37951334 |
|
NCBI chr16:7,395,502...7,415,846
Ensembl chr16:7,366,542...7,409,641 Ensembl chr16:7,366,542...7,409,641
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
multiple interactions |
ISO |
NDRG1 protein results in decreased susceptibility to [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone co-treated with bafilomycin A1] |
CTD |
PMID:24532803 |
|
NCBI chr 7:100,573,526...100,614,902
Ensembl chr 7:98,684,487...98,725,880
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases expression |
ISO |
bafilomycin A1 promotes the reaction [[Particulate Matter co-treated with Vitamin D] results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [[Silicon Dioxide co-treated with Vitamin D] results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [Particulate Matter results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [Silicon Dioxide results in increased expression of NFE2L2 protein] bafilomycin A1 results in increased expression of NFE2L2 protein |
CTD |
PMID:30698894 |
|
NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions increases expression |
ISO |
bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of NLRP3 protein] bafilomycin A1 results in increased expression of NLRP3 protein |
CTD |
PMID:32645460 |
|
NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
decreases expression |
ISO |
bafilomycin A1 results in decreased expression of NR5A1 protein |
CTD |
PMID:29524503 |
|
NCBI chr 3:42,874,505...42,896,109
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage increases expression |
ISO EXP |
[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] which results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [brazilin results in increased expression of PARP1 protein modified form]; bafilomycin A1 promotes the reaction [Flavanones results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [fosbretabulin results in increased cleavage of PARP1 protein]; BNIP3 mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; HIF1A mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein] bafilomycin A1 promotes the reaction [Methamphetamine results in increased cleavage of PARP1 protein] bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of PARP1 protein] bafilomycin A1 results in increased expression of PARP1 protein modified form |
CTD |
PMID:20876807 PMID:21616090 PMID:24321340 PMID:25981168 PMID:28063998 PMID:29111403 PMID:31310755 PMID:34374793 PMID:35022897 More...
|
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Dexamethasone results in decreased expression of PCNA mRNA] |
CTD |
PMID:33359579 |
|
NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pink1 |
PTEN induced kinase 1 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [Lidocaine results in increased expression of PINK1 protein] |
CTD |
PMID:37914286 |
|
NCBI chr 5:155,813,838...155,825,950
Ensembl chr 5:150,530,523...150,542,635
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO EXP |
bafilomycin A1 inhibits the reaction [2-chloroethyl ethyl sulfide results in decreased expression of PRKAA1 protein] bafilomycin A1 inhibits the reaction [Lidocaine results in increased phosphorylation of PRKAA1 protein] |
CTD |
PMID:37481222 PMID:37914286 |
|
NCBI chr 2:55,967,766...56,003,450
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [2-chloroethyl ethyl sulfide results in decreased expression of PRKAA2 protein] |
CTD |
PMID:37481222 |
|
NCBI chr 5:125,036,945...125,109,010
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Prkd2 |
protein kinase D2 |
multiple interactions |
ISO |
[PRKD2 protein affects the susceptibility to [erastin co-treated with bafilomycin A1]] which affects the abundance of Malondialdehyde; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTH1 protein]; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTL protein]; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of NCOA4 protein]; PRKD2 protein affects the susceptibility to [erastin co-treated with bafilomycin A1] |
CTD |
PMID:37951334 |
|
NCBI chr 1:86,640,095...86,670,476
Ensembl chr 1:77,513,986...77,542,376
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
bafilomycin A1 affects the localization of and results in increased activity of RELA protein |
CTD |
PMID:10339586 |
|
NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation multiple interactions |
ISO EXP |
bafilomycin A1 results in decreased phosphorylation of RPS6KB1 protein bafilomycin A1 inhibits the reaction [EGF protein results in increased activity of and results in increased phosphorylation of RPS6KB1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:22689575 PMID:31310755 |
|
NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rptor |
regulatory associated protein of MTOR, complex 1 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [Lidocaine results in decreased expression of [MTOR protein binds to RPTOR protein binds to MLST8 protein binds to PRAS40 protein binds to DEPTOR protein]] |
CTD |
PMID:37914286 |
|
NCBI chr10:105,376,943...105,675,416
Ensembl chr10:104,878,487...105,176,983
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA] |
CTD |
PMID:23111315 |
|
NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [resveratrol inhibits the reaction [Hydrogen Peroxide results in decreased expression of SIRT1 protein]] |
CTD |
PMID:24889822 |
|
NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc17a7 |
solute carrier family 17 member 7 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [SLC17A7 protein results in increased uptake of Excitatory Amino Acid Agents]; bafilomycin A1 inhibits the reaction [SLC17A7 protein results in increased uptake of Zinc]; bafilomycin A1 inhibits the reaction [SLC30A3 protein promotes the reaction [SLC17A7 protein results in increased uptake of Zinc]] |
CTD |
PMID:15860731 |
|
NCBI chr 1:104,786,172...104,798,049
Ensembl chr 1:95,649,745...95,661,588
|
|
G |
Slc30a3 |
solute carrier family 30 member 3 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [SLC30A3 protein promotes the reaction [SLC17A7 protein results in increased uptake of Zinc]] |
CTD |
PMID:15860731 |
|
NCBI chr 6:30,984,241...31,004,689
Ensembl chr 6:25,275,528...25,284,720
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions increases expression |
ISO |
bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein] bafilomycin A1 results in increased expression of SNAI1 protein |
CTD |
PMID:32645460 |
|
NCBI chr 3:176,667,476...176,671,965
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snca |
synuclein alpha |
multiple interactions increases expression |
ISO |
[bafilomycin A1 co-treated with Rotenone] results in increased expression of SNCA protein bafilomycin A1 results in increased expression of SNCA protein |
CTD |
PMID:26031332 |
|
NCBI chr 4:91,026,474...91,127,444
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Sort1 |
sortilin 1 |
decreases expression |
ISO |
bafilomycin A1 results in decreased expression of SORT1 protein |
CTD |
PMID:25805502 |
|
NCBI chr 2:198,609,466...198,690,481
Ensembl chr 2:195,924,099...196,002,354
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression multiple interactions |
ISO EXP |
bafilomycin A1 results in increased expression of SQSTM1 protein bafilomycin A1 promotes the reaction [Hydrogen Peroxide results in increased expression of SQSTM1 protein] [Resveratrol co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Silicon Dioxide co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Silicon Dioxide co-treated with Vitamin D co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [TNF protein co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Vitamin D co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; bafilomycin A1 inhibits the reaction [2-chloroethyl ethyl sulfide results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [dactolisib results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [Dexamethasone results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [pterostilbene inhibits the reaction [Ethanol results in increased expression of SQSTM1 protein]]; bafilomycin A1 inhibits the reaction [Resveratrol results in increased degradation of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [Sorafenib results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [metarrestin results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [Miconazole results in increased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [pachastrissamine analog promotes the reaction [KEAP1 protein binds to SQSTM1 protein]]; Fingolimod Hydrochloride affects the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]; sodium arsenite promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein] [bafilomycin A1 co-treated with Rotenone] results in increased expression of SQSTM1 protein; [bafilomycin A1 co-treated with Swainsonine] results in increased expression of SQSTM1 mRNA; [bafilomycin A1 co-treated with Swainsonine] results in increased lipidation of SQSTM1 protein; bafilomycin A1 inhibits the reaction [Resveratrol inhibits the reaction [Streptozocin results in increased expression of SQSTM1 protein]]; bafilomycin A1 inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; decamethrin promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]; Streptozocin promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein] |
CTD |
PMID:21778691 PMID:21858812 PMID:23151917 PMID:24145604 PMID:24238063 PMID:24889822 PMID:25939952 PMID:25943029 PMID:26031332 PMID:27305347 PMID:28125038 PMID:29248574 PMID:29524503 PMID:30698894 PMID:32186374 PMID:32645460 PMID:32981224 PMID:33124469 PMID:33359579 PMID:34405320 PMID:34520793 PMID:34580807 PMID:35123989 PMID:36070022 PMID:36402259 PMID:37481222 More...
|
|
NCBI chr10:35,026,598...35,037,750
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [2-chloroethyl ethyl sulfide results in decreased expression of STK11 protein] |
CTD |
PMID:37481222 |
|
NCBI chr 7:10,225,204...10,241,965
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Tbk1 |
TANK-binding kinase 1 |
multiple interactions |
ISO |
bafilomycin A1 promotes the reaction [Lipopolysaccharides results in increased phosphorylation of TBK1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein] |
CTD |
PMID:25780039 |
|
NCBI chr 7:58,963,319...58,996,357
Ensembl chr 7:57,077,830...57,110,892
|
|
G |
Tlr8 |
toll-like receptor 8 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [resiquimod results in increased activity of TLR8 protein] |
CTD |
PMID:21398612 |
|
NCBI chr X:30,708,714...30,733,104
Ensembl chr X:27,091,778...27,116,549
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO |
bafilomycin A1 results in increased expression of TNF mRNA [TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form; [TNF protein co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; resveratrol promotes the reaction [[TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form] |
CTD |
PMID:16932910 PMID:24145604 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tomm20 |
translocase of outer mitochondrial membrane 20 |
increases expression multiple interactions |
ISO |
bafilomycin A1 results in increased expression of TOMM20 protein Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of TOMM20 protein] |
CTD |
PMID:30209975 |
|
NCBI chr19:71,822,429...71,832,420
Ensembl chr19:54,923,402...54,935,198
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[bafilomycin A1 co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein; bafilomycin A1 inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein] |
CTD |
PMID:23380477 |
|
NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions |
EXP |
bafilomycin A1 affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide affects the reaction [Glucose affects the phosphorylation of ULK1 protein]] |
CTD |
PMID:29128638 |
|
NCBI chr12:51,511,492...51,537,746
Ensembl chr12:45,851,710...45,877,966
|
|
G |
Usp8 |
ubiquitin specific peptidase 8 |
multiple interactions |
ISO |
[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] which results in increased cleavage of PARP1 protein] |
CTD |
PMID:35022897 |
|
NCBI chr 3:113,962,136...114,009,683
Ensembl chr 3:113,962,164...114,009,666
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions increases expression |
ISO |
Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of VDAC1 protein] |
CTD |
PMID:30209975 |
|
NCBI chr10:37,029,377...37,060,542
Ensembl chr10:36,532,244...36,559,640
|
|
G |
Vdr |
vitamin D receptor |
multiple interactions |
ISO |
[bafilomycin A1 co-treated with Vitamin D] results in increased expression of VDR protein; [Silicon Dioxide co-treated with Vitamin D co-treated with bafilomycin A1] results in increased expression of VDR protein |
CTD |
PMID:30698894 |
|
NCBI chr 7:130,864,764...130,916,757
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vim |
vimentin |
multiple interactions increases expression |
ISO |
bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein] bafilomycin A1 results in increased expression of VIM protein |
CTD |
PMID:32645460 |
|
NCBI chr17:81,577,261...81,585,746
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
increases expression |
ISO |
bryostatin 1 results in increased expression of BIRC3 mRNA |
CTD |
PMID:14527959 |
|
NCBI chr 8:13,285,702...13,313,329
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Cd22 |
CD22 molecule |
increases expression |
ISO |
bryostatin 1 results in increased expression of CD22 protein |
CTD |
PMID:10741703 |
|
NCBI chr 1:95,243,785...95,270,430
Ensembl chr 1:86,117,459...86,132,322
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
bryostatin 1 inhibits the reaction [Paclitaxel results in increased activity of CDK1 protein] |
CTD |
PMID:10516758 |
|
NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,266,248...19,281,408
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
bryostatin 1 results in increased expression of F3 protein |
CTD |
PMID:25569083 |
|
NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
ISO |
bryostatin 1 analog results in decreased expression of IL10 mRNA; bryostatin 1 results in decreased expression of IL10 mRNA |
CTD |
PMID:15614042 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
decreases expression increases expression |
ISO |
bryostatin 1 analog results in decreased expression of IL12B mRNA bryostatin 1 results in increased expression of IL12B mRNA |
CTD |
PMID:15614042 |
|
NCBI chr10:29,390,300...29,405,194
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Itgax |
integrin subunit alpha X |
increases expression |
ISO |
bryostatin 1 results in increased expression of ITGAX protein |
CTD |
PMID:10741703 |
|
NCBI chr 1:192,140,089...192,171,151
Ensembl chr 1:182,719,609...182,740,698
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions decreases expression |
ISO |
[bryostatin 1 co-treated with mezerein] results in decreased expression of PRKCA protein bryostatin 1 results in decreased expression of PRKCA protein |
CTD |
PMID:8892972 |
|
NCBI chr10:93,388,991...93,787,617
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions decreases expression |
ISO |
[bryostatin 1 co-treated with mezerein] results in decreased expression of PRKCB protein; [bryostatin 1 co-treated with mezerein] results in decreased expression of PRKCB protein alternative form bryostatin 1 results in decreased expression of PRKCB protein; bryostatin 1 results in decreased expression of PRKCB protein alternative form |
CTD |
PMID:8892972 |
|
NCBI chr 1:186,263,397...186,594,743
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Prkcg |
protein kinase C, gamma |
multiple interactions decreases expression |
ISO |
[bryostatin 1 co-treated with mezerein] results in decreased expression of PRKCG protein bryostatin 1 results in decreased expression of PRKCG protein |
CTD |
PMID:8892972 |
|
NCBI chr 1:74,748,272...74,777,611
Ensembl chr 1:65,832,855...65,859,384
|
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
bryostatin 2 results in increased expression of F3 protein |
CTD |
PMID:25569083 |
|
NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:209,826,959...209,838,668
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
concanamycin A inhibits the reaction [enterotoxin C, staphylococcal results in increased expression of BAX protein] |
CTD |
PMID:27742270 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression multiple interactions |
ISO |
concanamycin A results in increased expression of BNIP3 mRNA lapatinib inhibits the reaction [concanamycin A results in increased expression of BNIP3 mRNA] |
CTD |
PMID:25981168 |
|
NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
concanamycin A inhibits the reaction [enterotoxin C, staphylococcal analog results in increased activity of CASP3 protein]; concanamycin A inhibits the reaction [enterotoxin C, staphylococcal results in increased activity of CASP3 protein] |
CTD |
PMID:27742270 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
concanamycin A inhibits the reaction [enterotoxin C, staphylococcal analog results in increased activity of CASP9 protein]; concanamycin A inhibits the reaction [enterotoxin C, staphylococcal results in increased activity of CASP9 protein] |
CTD |
PMID:27742270 |
|
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
concanamycin A results in increased expression of F3 protein |
CTD |
PMID:25569083 |
|
NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression multiple interactions |
ISO |
concanamycin A results in increased expression of HIF1A protein lapatinib inhibits the reaction [concanamycin A results in increased expression of HIF1A protein] |
CTD |
PMID:25981168 |
|
NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[lapatinib co-treated with concanamycin A] results in increased cleavage of PARP1 protein |
CTD |
PMID:25981168 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
|
G |
Actb |
actin, beta |
decreases response to substance |
ISO |
ACTB protein mutant form results in decreased susceptibility to latrunculin A |
CTD |
PMID:16685646 |
|
NCBI chr12:16,776,664...16,779,634
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
latrunculin A results in increased activity of CASP3 protein |
CTD |
PMID:16723733 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cdh1 |
cadherin 1 |
decreases uptake |
ISO |
latrunculin A results in decreased uptake of CDH1 protein modified form |
CTD |
PMID:20547569 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Ctnna1 |
catenin alpha 1 |
multiple interactions |
EXP |
latrunculin A affects the reaction [FSCN1 protein inhibits the reaction [CTNNA1 protein affects the susceptibility to Cisplatin]]; latrunculin A affects the reaction [FSCN2 protein inhibits the reaction [CTNNA1 protein affects the susceptibility to Cisplatin]] |
CTD |
PMID:27989596 |
|
NCBI chr18:27,002,330...27,135,009
Ensembl chr18:26,728,485...26,860,910
|
|
G |
Diaph1 |
diaphanous-related formin 1 |
affects localization |
ISO |
latrunculin A affects the localization of DIAPH1 protein |
CTD |
PMID:22918941 |
|
NCBI chr18:29,669,659...29,769,070
Ensembl chr18:29,669,659...29,769,172
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
multiple interactions |
EXP |
latrunculin A affects the reaction [FSCN1 protein inhibits the reaction [CTNNA1 protein affects the susceptibility to Cisplatin]] |
CTD |
PMID:27989596 |
|
NCBI chr12:16,710,601...16,723,734
Ensembl chr12:11,597,048...11,610,211
|
|
G |
Fscn2 |
fascin actin-bundling protein 2, retinal |
multiple interactions |
EXP |
latrunculin A affects the reaction [FSCN2 protein inhibits the reaction [CTNNA1 protein affects the susceptibility to Cisplatin]] |
CTD |
PMID:27989596 |
|
NCBI chr10:106,121,038...106,139,683
Ensembl chr10:105,634,783...105,641,322
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
latrunculin A inhibits the reaction [Asbestos, Crocidolite results in increased secretion of IL1B protein]; latrunculin A inhibits the reaction [Uric Acid results in increased secretion of IL1B protein] |
CTD |
PMID:18403674 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Itgb1 |
integrin subunit beta 1 |
decreases activity |
ISO |
latrunculin A results in decreased activity of ITGB1 protein |
CTD |
PMID:16723733 |
|
NCBI chr19:73,602,277...73,650,271
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Prlr |
prolactin receptor |
decreases uptake |
ISO |
latrunculin A results in decreased uptake of PRLR protein |
CTD |
PMID:20547569 |
|
NCBI chr 2:60,861,391...61,051,883
Ensembl chr 2:59,134,588...59,324,718
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression multiple interactions |
EXP |
latrunculin B results in decreased expression of ACTA2 mRNA latrunculin B inhibits the reaction [RHOA protein results in increased expression of ACTA2 mRNA] |
CTD |
PMID:11035001 |
|
NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Aurkb |
aurora kinase B |
multiple interactions |
ISO |
latrunculin B inhibits the reaction [Silver results in increased phosphorylation of AURKB protein] |
CTD |
PMID:28499611 |
|
NCBI chr10:54,243,116...54,249,675
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Gata4 |
GATA binding protein 4 |
multiple interactions |
EXP |
latrunculin B inhibits the reaction [Phenylephrine results in increased activity of GATA4 protein] |
CTD |
PMID:11739382 |
|
NCBI chr15:41,635,572...41,707,252
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression multiple interactions |
ISO |
latrunculin B results in increased expression of GDF15 mRNA; latrunculin B results in increased expression of GDF15 protein [SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [latrunculin B results in increased expression of GDF15 protein] |
CTD |
PMID:23996089 |
|
NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
latrunculin B promotes the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA] |
CTD |
PMID:12799187 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
latrunculin B promotes the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA] jasplakinolide inhibits the reaction [latrunculin B promotes the reaction [IL1B protein results in increased expression of NOS2 protein]]; latrunculin B promotes the reaction [IL1B protein results in increased expression of NOS2 protein] |
CTD |
PMID:11502570 PMID:12799187 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
latrunculin B inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:11739382 |
|
NCBI chr11:97,462,025...97,529,193
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
latrunculin B inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:11739382 |
|
NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Myod1 |
myogenic differentiation 1 |
decreases expression |
ISO |
latrunculin B results in decreased expression of MYOD1 protein |
CTD |
PMID:15252113 |
|
NCBI chr 1:106,021,161...106,023,871
Ensembl chr 1:96,884,948...96,887,554
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
[latrunculin B results in decreased activity of SRF protein] which results in increased expression of NOS2 protein; latrunculin B promotes the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA] jasplakinolide inhibits the reaction [latrunculin B promotes the reaction [IL1B protein results in increased expression of NOS2 protein]]; latrunculin B promotes the reaction [IL1B protein results in increased expression of NOS2 protein] |
CTD |
PMID:11502570 PMID:12799187 |
|
NCBI chr10:64,313,335...64,349,221
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ppp1r9a |
protein phosphatase 1, regulatory subunit 9A |
affects localization |
EXP |
latrunculin B affects the localization of PPP1R9A protein |
CTD |
PMID:12052877 |
|
NCBI chr 4:33,936,949...34,258,927
Ensembl chr 4:33,024,450...33,286,907
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions |
EXP |
latrunculin B inhibits the reaction [RHOA protein results in increased expression of ACTA2 mRNA] |
CTD |
PMID:11035001 |
|
NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Srf |
serum response factor |
decreases activity multiple interactions |
ISO |
latrunculin B results in decreased activity of SRF protein [latrunculin B results in decreased activity of SRF protein] which results in increased expression of NOS2 protein |
CTD |
PMID:11502570 |
|
NCBI chr 9:21,924,050...21,933,338
Ensembl chr 9:14,426,472...14,435,733
|
|
G |
Tagln |
transgelin |
decreases expression |
EXP |
latrunculin B results in decreased expression of TAGLN mRNA |
CTD |
PMID:11035001 |
|
NCBI chr 8:55,121,647...55,127,121
Ensembl chr 8:46,222,472...46,230,668
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
latrunculin B promotes the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA] |
CTD |
PMID:12799187 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Monensin inhibits the reaction [[Ketamine results in increased cleavage of APP protein] which results in increased abundance of amyloid beta-protein (1-40)]; Monensin inhibits the reaction [[Ketamine results in increased cleavage of APP protein] which results in increased abundance of amyloid beta-protein (1-42)] Monensin inhibits the reaction [Ketamine results in decreased expression of and results in increased cleavage of APP protein] |
CTD |
PMID:35378374 |
|
NCBI chr11:37,506,207...37,724,351
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Atp7a |
ATPase copper transporting alpha |
multiple interactions |
ISO |
Monensin inhibits the reaction [ATP7A protein affects the localization of Doxorubicin] |
CTD |
PMID:17510416 |
|
NCBI chr X:75,159,635...75,267,094
Ensembl chr X:71,094,202...71,198,354
|
|
G |
Bace1 |
beta-secretase 1 |
multiple interactions |
ISO |
Monensin inhibits the reaction [Ketamine results in increased expression of and affects the localization of BACE1 protein] |
CTD |
PMID:35378374 |
|
NCBI chr 8:55,038,842...55,061,138
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression |
ISO |
Monensin results in increased expression of BNIP3 protein |
CTD |
PMID:30718715 |
|
NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO |
Lithium inhibits the reaction [Monensin results in increased activity of CASP3 protein] |
CTD |
PMID:20799912 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases activity |
ISO |
Lithium inhibits the reaction [Monensin results in increased activity of CASP7 protein] |
CTD |
PMID:20799912 |
|
NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
Monensin inhibits the reaction [kaempferol results in increased secretion of CSF2 protein]; Monensin inhibits the reaction [Quercetin results in increased secretion of CSF2 protein] |
CTD |
PMID:18346843 |
|
NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
EXP |
[EGF protein co-treated with Monensin] results in increased expression of MYC mRNA |
CTD |
PMID:12632255 |
|
NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Il6 |
interleukin 6 |
decreases secretion |
ISO |
Monensin results in decreased secretion of IL6 protein |
CTD |
PMID:11216681 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
decreases degradation |
EXP |
Monensin results in decreased degradation of INS1 protein |
CTD |
PMID:2645939 |
|
NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
EXP |
[EGF protein co-treated with Monensin] results in increased expression of MYC mRNA |
CTD |
PMID:12632255 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
Monensin results in increased cleavage of PARP1 protein |
CTD |
PMID:30718715 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Slc6a2 |
solute carrier family 6 member 2 |
multiple interactions |
ISO |
Monensin promotes the reaction [para-methyl-4-methylaminorex inhibits the reaction [SLC6A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]] |
CTD |
PMID:29908239 |
|
NCBI chr19:30,183,289...30,228,292
Ensembl chr19:14,010,386...14,050,357
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
multiple interactions |
ISO |
Monensin promotes the reaction [para-methyl-4-methylaminorex inhibits the reaction [SLC6A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]] |
CTD |
PMID:29908239 |
|
NCBI chr 1:31,537,990...31,578,962
Ensembl chr 1:29,709,443...29,750,413
|
|
G |
Slc6a4 |
solute carrier family 6 member 4 |
multiple interactions |
ISO |
Monensin promotes the reaction [para-methyl-4-methylaminorex inhibits the reaction [SLC6A4 protein results in increased uptake of Serotonin]] |
CTD |
PMID:29908239 |
|
NCBI chr10:62,322,688...62,357,060
Ensembl chr10:61,826,123...61,858,384
|
|
G |
Trpm2 |
transient receptor potential cation channel, subfamily M, member 2 |
decreases expression multiple interactions increases expression |
ISO |
Monensin results in decreased expression of TRPM2 protein alternative form Lithium inhibits the reaction [Monensin results in increased expression of TRPM2 protein alternative form] |
CTD |
PMID:20799912 |
|
NCBI chr20:10,703,190...10,752,795
Ensembl chr20:10,707,014...10,753,181
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
increases response to substance |
ISO |
ZEB1 protein results in increased susceptibility to Monensin |
CTD |
PMID:30718715 |
|
NCBI chr17:56,644,397...56,811,155
Ensembl chr17:51,948,948...52,115,214
|
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
oridonin binds to and affects the folding of ALB protein |
CTD |
PMID:25816984 |
|
NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX mRNA]; oridonin inhibits the reaction [Kainic Acid results in increased expression of BAX mRNA] |
CTD |
PMID:31430510 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
oridonin analog results in decreased expression of BCL2 protein; oridonin results in decreased expression of BCL2 protein oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 mRNA]; oridonin inhibits the reaction [Kainic Acid results in decreased expression of BCL2 mRNA] |
CTD |
PMID:16019488 PMID:31430510 PMID:31594861 |
|
NCBI chr13:23,204,464...23,366,900
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
oridonin analog results in decreased expression of BIRC5 protein |
CTD |
PMID:31594861 |
|
NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO EXP |
oridonin results in increased cleavage of CASP3 protein oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP3 protein]; oridonin inhibits the reaction [Kainic Acid results in increased activity of CASP3 protein] |
CTD |
PMID:16019488 PMID:31430510 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of CAT protein]; oridonin inhibits the reaction [Kainic Acid results in decreased activity of CAT protein] |
CTD |
PMID:31430510 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
oridonin analog results in decreased expression of CCND1 protein |
CTD |
PMID:31594861 |
|
NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdh1 |
cadherin 1 |
increases expression multiple interactions |
ISO |
oridonin results in increased expression of CDH1 mRNA; oridonin results in increased expression of CDH1 protein oridonin inhibits the reaction [TGFB1 protein results in increased expression of CDH1 mRNA]; oridonin inhibits the reaction [TGFB1 protein results in increased expression of CDH1 protein] |
CTD |
PMID:30243739 |
|
NCBI chr19:51,402,178...51,471,572
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions decreases expression |
ISO |
oridonin inhibits the reaction [TGFB1 protein results in decreased expression of CDH2 mRNA]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of CDH2 protein] oridonin results in decreased expression of CDH2 mRNA; oridonin results in decreased expression of CDH2 protein |
CTD |
PMID:30243739 |
|
NCBI chr18:8,051,097...8,265,288
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
oridonin analog inhibits the reaction [EGF protein promotes the reaction [EGFR protein modified form binds to STAT3 protein]]; oridonin analog inhibits the reaction [EGF protein promotes the reaction [SRC protein modified form binds to STAT3 protein]]; oridonin analog inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:31594861 |
|
NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
oridonin analog inhibits the reaction [EGF protein promotes the reaction [EGFR protein modified form binds to STAT3 protein]]; oridonin analog inhibits the reaction [EGFR protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:31594861 |
|
NCBI chr14:95,378,626...95,551,358
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Glul |
glutamate-ammonia ligase |
multiple interactions |
EXP |
oridonin inhibits the reaction [Kainic Acid results in decreased expression of GLUL mRNA] |
CTD |
PMID:31430510 |
|
NCBI chr13:68,519,500...68,585,554
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased activity of GSR protein]; oridonin inhibits the reaction [Kainic Acid results in decreased activity of GSR protein] |
CTD |
PMID:31430510 |
|
NCBI chr16:65,185,574...65,228,742
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP |
oridonin results in increased expression of HMOX1 mRNA; oridonin results in increased expression of HMOX1 protein oridonin results in increased expression of and results in increased activity of HMOX1 protein |
CTD |
PMID:18351433 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ifng |
interferon gamma |
decreases expression multiple interactions |
EXP ISO |
oridonin results in decreased expression of IFNG protein oridonin analog inhibits the reaction [IFNG protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:18351433 PMID:31594861 |
|
NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
increases expression |
EXP |
oridonin results in increased expression of IL10 protein |
CTD |
PMID:18351433 |
|
NCBI chr13:45,024,921...45,029,586
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL1B protein]; oridonin inhibits the reaction [Kainic Acid results in increased expression of IL1B protein] |
CTD |
PMID:31430510 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
decreases expression |
EXP |
oridonin results in decreased expression of IL2 protein |
CTD |
PMID:18351433 |
|
NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]; oridonin inhibits the reaction [Kainic Acid results in increased expression of IL6 protein] oridonin analog inhibits the reaction [IL6 protein affects the localization of STAT3 protein]; oridonin analog inhibits the reaction [IL6 protein promotes the reaction [JAK1 protein modified form binds to STAT3 protein]]; oridonin analog inhibits the reaction [IL6 protein promotes the reaction [STAT1 protein binds to STAT3 protein]]; oridonin analog inhibits the reaction [IL6 protein promotes the reaction [STAT3 protein binds to STAT3 protein]]; oridonin analog inhibits the reaction [IL6 protein results in increased expression of STAT3 mRNA]; oridonin analog inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:31430510 PMID:31594861 |
|
NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Impdh2 |
inosine monophosphate dehydrogenase 2 |
decreases activity |
ISO |
oridonin results in decreased activity of IMPDH2 protein |
CTD |
PMID:37871880 |
|
NCBI chr 8:118,135,204...118,139,892
Ensembl chr 8:109,256,728...109,261,359
|
|
G |
Jak1 |
Janus kinase 1 |
multiple interactions |
ISO |
oridonin analog inhibits the reaction [IL6 protein promotes the reaction [JAK1 protein modified form binds to STAT3 protein]]; oridonin analog inhibits the reaction [JAK1 protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:31594861 |
|
NCBI chr 5:120,895,606...121,004,207
Ensembl chr 5:115,780,248...115,888,926
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
oridonin analog results in decreased expression of MKI67 protein |
CTD |
PMID:31594861 |
|
NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression |
ISO |
oridonin analog results in decreased expression of MMP2 protein |
CTD |
PMID:31594861 |
|
NCBI chr19:30,327,643...30,355,856
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression |
ISO |
oridonin analog results in decreased expression of MMP9 protein |
CTD |
PMID:31594861 |
|
NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
oridonin analog results in decreased expression of MYC protein |
CTD |
PMID:31594861 |
|
NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
oridonin results in increased cleavage of PARP1 protein oridonin analog results in decreased expression of and results in increased cleavage of PARP1 protein |
CTD |
PMID:16019488 PMID:31594861 |
|
NCBI chr13:94,839,484...94,871,295
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of PTGS2 protein]; oridonin inhibits the reaction [Kainic Acid results in increased expression of PTGS2 protein] |
CTD |
PMID:31430510 |
|
NCBI chr13:64,714,063...64,722,320
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rangap1 |
RAN GTPase activating protein 1 |
multiple interactions |
ISO |
oridonin results in decreased expression of and affects the localization of RANGAP1 protein |
CTD |
PMID:25746355 |
|
NCBI chr 7:115,104,820...115,130,564
Ensembl chr 7:113,224,703...113,250,438
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions |
ISO |
oridonin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:30243739 |
|
NCBI chr18:72,124,792...72,193,345
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
ISO |
oridonin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:30243739 |
|
NCBI chr 8:73,022,204...73,132,324
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
decreases expression multiple interactions |
ISO |
oridonin results in decreased expression of SNAI1 mRNA; oridonin results in decreased expression of SNAI1 protein oridonin inhibits the reaction [TGFB1 protein results in decreased expression of SNAI1 mRNA]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of SNAI1 protein] |
CTD |
PMID:30243739 |
|
NCBI chr 3:176,667,476...176,671,965
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
decreases expression multiple interactions |
ISO |
oridonin results in decreased expression of SNAI2 mRNA; oridonin results in decreased expression of SNAI2 protein oridonin inhibits the reaction [TGFB1 protein results in decreased expression of SNAI2 mRNA]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of SNAI2 protein] |
CTD |
PMID:30243739 |
|
NCBI chr11:99,686,934...99,690,349
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
oridonin analog inhibits the reaction [EGF protein promotes the reaction [SRC protein modified form binds to STAT3 protein]]; oridonin analog inhibits the reaction [SRC protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:31594861 |
|
NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
oridonin analog inhibits the reaction [IL6 protein promotes the reaction [STAT1 protein binds to STAT3 protein]] |
CTD |
PMID:31594861 |
|
NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions decreases phosphorylation |
ISO |
oridonin analog inhibits the reaction [IFNG protein results in increased phosphorylation of STAT3 protein] oridonin analog results in decreased phosphorylation of STAT3 protein oridonin analog binds to and results in decreased stability of STAT3 protein; oridonin analog inhibits the reaction [EGF protein promotes the reaction [EGFR protein modified form binds to STAT3 protein]]; oridonin analog inhibits the reaction [EGF protein promotes the reaction [SRC protein modified form binds to STAT3 protein]]; oridonin analog inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; oridonin analog inhibits the reaction [EGFR protein results in increased phosphorylation of STAT3 protein]; oridonin analog inhibits the reaction [IFNG protein results in increased phosphorylation of STAT3 protein]; oridonin analog inhibits the reaction [IL6 protein affects the localization of STAT3 protein]; oridonin analog inhibits the reaction [IL6 protein promotes the reaction [JAK1 protein modified form binds to STAT3 protein]]; oridonin analog inhibits the reaction [IL6 protein promotes the reaction [STAT1 protein binds to STAT3 protein]]; oridonin analog inhibits the reaction [IL6 protein promotes the reaction [STAT3 protein binds to STAT3 protein]]; oridonin analog inhibits the reaction [IL6 protein results in increased expression of STAT3 mRNA]; oridonin analog inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; oridonin analog inhibits the reaction [JAK1 protein results in increased phosphorylation of STAT3 protein]; oridonin analog inhibits the reaction [SRC protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:31594861 |
|
NCBI chr10:86,311,528...86,363,513
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression multiple interactions |
EXP ISO |
oridonin results in increased expression of TGFB1 protein oridonin inhibits the reaction [TGFB1 protein results in decreased expression of CDH2 mRNA]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of CDH2 protein]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of SNAI1 mRNA]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of SNAI1 protein]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of SNAI2 mRNA]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of SNAI2 protein]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of VIM mRNA]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of VIM protein]; oridonin inhibits the reaction [TGFB1 protein results in increased expression of CDH1 mRNA]; oridonin inhibits the reaction [TGFB1 protein results in increased expression of CDH1 protein]; oridonin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; oridonin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:18351433 PMID:30243739 |
|
NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of TH mRNA] |
CTD |
PMID:31430510 |
|
NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
oridonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]; oridonin inhibits the reaction [Kainic Acid results in increased expression of TNF protein] |
CTD |
PMID:31430510 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vim |
vimentin |
multiple interactions decreases expression |
ISO |
oridonin inhibits the reaction [TGFB1 protein results in decreased expression of VIM mRNA]; oridonin inhibits the reaction [TGFB1 protein results in decreased expression of VIM protein] oridonin results in decreased expression of VIM mRNA; oridonin results in decreased expression of VIM protein |
CTD |
PMID:30243739 |
|
NCBI chr17:81,577,261...81,585,746
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[Ryanodine co-treated with Halothane] results in increased expression of BAX mRNA |
CTD |
PMID:32795494 |
|
NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions |
ISO |
[Ryanodine co-treated with Halothane] results in increased expression of BCL2L11 mRNA |
CTD |
PMID:32795494 |
|
NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
[Ryanodine co-treated with Thioctic Acid] results in decreased activity of CASP3 protein; Ryanodine inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein] |
CTD |
PMID:17079870 |
|
NCBI chr16:52,395,539...52,413,794
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
[bastadin 12 co-treated with Ryanodine co-treated with Dizocilpine Maleate] inhibits the reaction [tetrabromobisphenol A results in decreased activity of CAT protein] |
CTD |
PMID:27718046 |
|
NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
Ryanodine inhibits the reaction [Nicotine results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:21113126 |
|
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of CXCL2 mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr14:17,465,210...17,467,255
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of DDIT3 mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
Ryanodine inhibits the reaction [FASL protein affects the localization of Calcium] |
CTD |
PMID:20200208 |
|
NCBI chr13:76,680,885...76,706,042
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fkbp1a |
FKBP prolyl isomerase 1A |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of FKBP1A mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 3:160,500,748...160,520,492
Ensembl chr 3:140,040,278...140,060,743
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
multiple interactions |
ISO |
[Ryanodine co-treated with Halothane] results in increased expression of FKBP1B mRNA; Ryanodine inhibits the reaction [FKBP1B gene mutant form inhibits the reaction [Acetylcholine affects the localization of and affects the abundance of Calcium]] |
CTD |
PMID:17261647 PMID:32795494 |
|
NCBI chr 6:33,551,583...33,570,055
Ensembl chr 6:27,838,802...27,848,653
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of GPT protein] |
CTD |
PMID:32795494 |
|
NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[Ryanodine co-treated with Halothane] results in increased expression of HMOX1 mRNA |
CTD |
PMID:32795494 |
|
NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Homer1 |
homer scaffold protein 1 |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of HOMER1 mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 2:26,279,012...26,388,279
Ensembl chr 2:24,543,093...24,644,785
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Ryanodine co-treated with Halothane] results in increased expression of IL1B mRNA |
CTD |
PMID:32795494 |
|
NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of ITGAM mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 1:192,089,496...192,139,947
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
NR4A1 protein inhibits the reaction [Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR protein]]; Ryanodine inhibits the reaction [Colforsin results in increased expression of NR4A1 mRNA]; Ryanodine inhibits the reaction [Colforsin results in increased expression of NR4A1 protein] |
CTD |
PMID:23183170 |
|
NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Mustard Gas results in increased activity of PLAU protein] |
CTD |
PMID:9101041 |
|
NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Ryr1 |
ryanodine receptor 1 |
multiple interactions |
ISO |
Triclosan promotes the reaction [Ryanodine binds to RYR1 protein] 2,3,6,2',3',6'-hexachlorobiphenyl affects the reaction [Ryanodine binds to RYR1 protein]; chlorantranilipole promotes the reaction [Ryanodine binds to RYR1 protein]; flubendiamide promotes the reaction [Ryanodine binds to RYR1 protein] |
CTD |
PMID:18795164 PMID:18954145 PMID:30329129 |
|
NCBI chr 1:93,420,078...93,551,305
Ensembl chr 1:84,292,578...84,423,812
|
|
G |
Ryr2 |
ryanodine receptor 2 |
affects binding multiple interactions |
ISO EXP |
Ryanodine binds to RYR2 protein decamethrin promotes the reaction [Ryanodine binds to RYR2 protein] 2,3,6,2',3',6'-hexachlorobiphenyl affects the reaction [Ryanodine binds to RYR2 protein] |
CTD |
PMID:11278295 PMID:18954145 PMID:31166131 |
|
NCBI chr17:63,081,527...63,667,141
Ensembl chr17:58,389,925...58,975,142
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of S100A8 mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 2:178,464,095...178,465,223
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of S100A9 mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 2:178,487,941...178,490,622
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
NR4A1 protein inhibits the reaction [Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR protein]]; Ryanodine inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR protein] |
CTD |
PMID:23183170 |
|
NCBI chr16:72,969,824...72,974,447
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of TNF mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
Ryanodine promotes the reaction [Halothane results in increased expression of VCAM1 mRNA] |
CTD |
PMID:32795494 |
|
NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:204,038,114...204,057,958
|
|